EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

CAR NK cell therapy for solid tumors: potential and challenges

Yanlin Yu, Mitchell Ho iD

Antibody Therapeutics · 16.10.2025 · 8 (4) · 275-289

DOI: 10.1093/abt/tbaf019 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibody Therapeutics, online erschienen am 11.09.2025. Verfasst von Yanlin Yu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Antibody Engineering Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, Intramural Research Program of the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CAR-T cell therapy has shown promise but is constrained by side effects and limited efficacy in treating solid tumors. Compared to CAR-T cells, CAR natural killer (NK) cells derived from multiple versatile sources exhibit more favorable safety profiles and possess the unique ability to refine cytotoxic activity, serve as off-the-shelf options, and target a broad range of tumors. However, several challenges still impede the development and implementation of CAR NK cell therapy for solid tumors. This review article outlines the therapeutic strategies, advantages, limitations, and potential solutions, while providing insight into the future landscape by challenging current knowledge in the field. It also discusses optimizing CAR NK cell structure, addressing obstacles in the clinical utility of CAR NK cell therapy, and integrating it into standard cancer treatment regimens. Ultimately, we aim to navigate the crucial challenges in treating solid tumors and explore the future of this approach.

Schlagwörter

Stichwörter der Autor:innen

CAR NK cell therapycancer treatmentnatural killer (NK) cellsolid tumor

Autor:innen und Institutionen

  • Antibody Engineering Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.

ORCID-Profile: Mitchell Ho

Förderung

  • Intramural NIH HHS
  • Intramural Research Program of the National Institutes of Health

Zitieren

APA

Yu, Y., & Ho, M. (2025). CAR NK cell therapy for solid tumors: potential and challenges. Antibody Therapeutics, 8(4), 275-289. https://doi.org/10.1093/abt/tbaf019

Vancouver

Yu Y, Ho M. CAR NK cell therapy for solid tumors: potential and challenges. Antibody Therapeutics. 2025;8(4):275-289. doi:10.1093/abt/tbaf019

BibTeX
@article{Yu2025,
  author = {Yu, Yanlin and Ho, Mitchell},
  title = {CAR NK cell therapy for solid tumors: potential and challenges},
  journal = {Antibody Therapeutics},
  year = {2025},
  volume = {8},
  number = {4},
  pages = {275--289},
  doi = {10.1093/abt/tbaf019}
}
Kostenlos starten →